超声最大径线测量在乳腺癌新辅助化疗疗效评价中的价值  

Clinical Observation of Ultrasonic Maximum Diameter line Measurement in Neoadjuvant Chemotherapy for the Effect Assessment of Breast Cancer

作　　者：陈元元[1] 马蓉[1] 孙临华[1] 李有怀[1] 王建生[2] 

机构地区：[1]宝鸡市中心医院乳腺科,陕西宝鸡721008 [2]西安交通大学医学院第一附属医院肿瘤外科,陕西宝鸡710061

出　　处：《中国医药指南》2015年第12期6-8,共3页Guide of China Medicine

摘　　要：目的观察多普勒超声测量病灶最大径线在乳腺癌新辅助化疗疗效评估中的应用价值。方法利用多普勒超声对91例接受新辅助化疗治疗前与治疗后的乳腺癌病灶最大径线进行测量,并与术后组织病理检查结果对比。结果化疗疗效的总有效率为74.73%,总的无效率为25.27%;超声组对其总体疗效的评价为74.7%,与病理组的评价标准(86.8%)相比稍低;而对其亚组分析后发现乳腺导管癌(P<0.05),晚期Ⅲ期患者(P<0.05),内分泌有反应型的患者(0.042),其超声的评价标准不能达到病理标准,且差异具有统计学意义;而对于小叶癌(P>0.05),早期的乳腺癌(Ⅰ+Ⅱ)患者(P>0.05),内分泌无反应型的患者(P>0.05),使用超声评价化疗疗效可以达到与病理评价类似的效果;其次肿块的大小不会影响超声评价的准确性。结论单纯使用超声测量最大径线的方法对乳腺癌新辅助化疗效果评估具有一定的作用。Objective To investigate the application of doppler ultrasound in the evaluation of the effect of neoadjuvant chemotherapy of breast cancer. Methods Using doppler ultrasonography in 91 cases that have received neoadjuvant chemotherapy of breast cancer to measure maximum diameters and Comparre with postoperative pathological findings. Results The total effective rate of chemotherapy was 74.73% and total inefficiency is 25.27%; The evaluation of curative effect for ultrasound group is 74.7% thich is lower than that of pathological group （86.8%）; Results of subgroup analysis showed that ultrasonic evaluation standard can not reach the standard pathology for those patients with mammary ductal carcinoma （P〈0.05）, adanced stage M （/〈0.05） and endocrine （0.042）, however, ultrasonic evaluation standard have similarly Effect with pathology standard for those patients with lobular carcinoma （P〉0.05）, early breast cancer （ I ＋ Ⅱ ） （P〉0.05）, no reactive endocrine of patients （P〉0.05）; finally, lump size will not affect the accuracy of the ultrasonic evaluation. Conclusion The single use of ultrasonic measurement of maximum diameter line to evaluate effect of neoadjuvant chemotherapy for breast cancer is is limited, So we must Combine with other methods to assess the chemotherapeutic efficacy.

关 键 词：超声 乳腺癌 新辅助化疗 效果评估 

分 类 号：R737.9[医药卫生—肿瘤]